ID   Raji
AC   CVCL_0511
SY   RAJI; P1-Raji; GM04671
DR   BTO; BTO:0001154
DR   CLO; CLO_0008734
DR   CLO; CLO_0019014
DR   CLO; CLO_0050995
DR   EFO; EFO_0002324
DR   MCCL; MCC:0000409
DR   CLDB; cl4086
DR   CLDB; cl4088
DR   CLDB; cl4089
DR   CLDB; cl4090
DR   CLDB; cl4091
DR   CLDB; cl4092
DR   CLDB; cl4990
DR   Abcam; ab271145
DR   Abcam; ab275473
DR   AddexBio; C0003009/4668
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CCL-86
DR   ATCC; CRL-7936
DR   BCRC; 60116
DR   BCRJ; 0211
DR   BioGRID_ORCS_Cell_line; 272
DR   BioSample; SAMN01821589
DR   BioSample; SAMN01821656
DR   BioSample; SAMN01821715
DR   BioSample; SAMN01821738
DR   BioSample; SAMN03473128
DR   BioSample; SAMN10987653
DR   cancercelllines; CVCL_0511
DR   CCRID; 1101HUM-PUMC000046
DR   CCRID; 1102HUM-NIFDC00025
DR   CCRID; 3101HUMTCHu44
DR   CCRID; 4201HUM-CCTCC00191
DR   CCTCC; GDC0191
DR   Cell_Model_Passport; SIDM00844
DR   CGH-DB; 9204-4
DR   ChEMBL-Cells; CHEMBL3307663
DR   ChEMBL-Targets; CHEMBL614628
DR   CLS; 300359
DR   Coriell; GM04671
DR   Cosmic; 687850
DR   Cosmic; 850211
DR   Cosmic; 850387
DR   Cosmic; 851997
DR   Cosmic; 909262
DR   Cosmic; 919136
DR   Cosmic; 929816
DR   Cosmic; 931110
DR   Cosmic; 932761
DR   Cosmic; 991549
DR   Cosmic; 998718
DR   Cosmic; 1019313
DR   Cosmic; 1037703
DR   Cosmic; 1070707
DR   Cosmic; 1071883
DR   Cosmic; 1082517
DR   Cosmic; 1093788
DR   Cosmic; 1107179
DR   Cosmic; 1127266
DR   Cosmic; 1176615
DR   Cosmic; 1191688
DR   Cosmic; 1483367
DR   Cosmic; 1517664
DR   Cosmic; 1818346
DR   Cosmic; 2301566
DR   Cosmic; 2361386
DR   Cosmic; 2649241
DR   Cosmic; 2814541
DR   Cosmic; 2815215
DR   Cosmic; 2823074
DR   Cosmic-CLP; 909262
DR   DepMap; ACH-000654
DR   DSMZ; ACC-319
DR   DSMZCellDive; ACC-319
DR   ECACC; 85011429
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS260AAA
DR   GDSC; 909262
DR   GEO; GSM33154
DR   GEO; GSM99387
DR   GEO; GSM887523
DR   GEO; GSM888605
DR   GEO; GSM1374840
DR   GEO; GSM1374841
DR   GEO; GSM1374842
DR   GEO; GSM1602232
DR   GEO; GSM1602233
DR   GEO; GSM1602234
DR   GEO; GSM1602235
DR   GEO; GSM1602236
DR   GEO; GSM1602237
DR   GEO; GSM1602238
DR   GEO; GSM1602241
DR   GEO; GSM1602242
DR   GEO; GSM1602243
DR   GEO; GSM1602244
DR   GEO; GSM1670357
DR   GEO; GSM3150253
DR   HIVReagentProgram; ARP-9944
DR   IARC_TP53; 704
DR   IARC_TP53; 21706
DR   ICLC; HTL00002
DR   IHW; IHW04994
DR   IGRhCellID; Raji
DR   IPD-IMGT/HLA; 11295
DR   IZSLER; BS TCL 54
DR   JCRB; IFO50046
DR   JCRB; JCRB9012
DR   LiGeA; CCLE_651
DR   LINCS_LDP; LCL-2025
DR   Lonza; 726
DR   NCBI_Iran; C127
DR   PharmacoDB; Raji_1282_2019
DR   PRIDE; PXD005704
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0511
DR   PubChem_Cell_line; CVCL_0511
DR   RCB; RCB1647
DR   RCB; RCB3673
DR   TKG; TKG 0371
DR   TOKU-E; 2967
DR   Wikidata; Q4215980
RX   CelloPub=CLPUB00447;
RX   CelloPub=CLPUB00458;
RX   DOI=10.1007/BF02618370;
RX   PubMed=170370;
RX   PubMed=216485;
RX   PubMed=1086134;
RX   PubMed=1915267;
RX   PubMed=2140233;
RX   PubMed=2470097;
RX   PubMed=2985879;
RX   PubMed=2998993;
RX   PubMed=3026973;
RX   PubMed=3034807;
RX   PubMed=3080238;
RX   PubMed=3159941;
RX   PubMed=3518877;
RX   PubMed=3874327;
RX   PubMed=3905596;
RX   PubMed=4122458;
RX   PubMed=4169243;
RX   PubMed=4321017;
RX   PubMed=4321974;
RX   PubMed=4325933;
RX   PubMed=4347031;
RX   PubMed=4364259;
RX   PubMed=4366935;
RX   PubMed=4550511;
RX   PubMed=4736620;
RX   PubMed=4894370;
RX   PubMed=6018567;
RX   PubMed=6231253;
RX   PubMed=6265077;
RX   PubMed=6286763;
RX   PubMed=6306472;
RX   PubMed=6419122;
RX   PubMed=6500159;
RX   PubMed=6547209;
RX   PubMed=6582512;
RX   PubMed=6592381;
RX   PubMed=6600440;
RX   PubMed=6806672;
RX   PubMed=6954533;
RX   PubMed=7060222;
RX   PubMed=7316467;
RX   PubMed=7849311;
RX   PubMed=8316623;
RX   PubMed=8344493;
RX   PubMed=8515068;
RX   PubMed=8547074;
RX   PubMed=8558913;
RX   PubMed=8847894;
RX   PubMed=9192833;
RX   PubMed=9473234;
RX   PubMed=9510473;
RX   PubMed=9685479;
RX   PubMed=9737686;
RX   PubMed=9738977;
RX   PubMed=9787181;
RX   PubMed=9973220;
RX   PubMed=10739008;
RX   PubMed=11226526;
RX   PubMed=11416159;
RX   PubMed=12145705;
RX   PubMed=12967475;
RX   PubMed=14086209;
RX   PubMed=14982850;
RX   PubMed=15028022;
RX   PubMed=15457187;
RX   PubMed=15901131;
RX   PubMed=18357372;
RX   PubMed=19358282;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20454443;
RX   PubMed=22460905;
RX   PubMed=22885699;
RX   PubMed=24590883;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=27397505;
RX   PubMed=27566572;
RX   PubMed=28196595;
RX   PubMed=29892436;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/Raji_cell
WW   https://www.atcc.org/en/support/technical-support/faqs/ccl-86-morphology-and-growth
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/Raji_Farnham_protocol.pdf
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/r/cell-lines-detail-27.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: African; Nigerian.
CC   Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572).
CC   Virology: Contains 50-60 integrated copies of the EBV genome. One copy is integrated in intron 1 of the BACH2 gene (PubMed=14982850).
CC   Doubling time: 23.2 hours (PubMed=8847894); ~24-36 hours (DSMZ=ACC-319); ~20 hours (HIVReagentProgram=ARP-9944).
CC   HLA typing: A*03:01,03:01; B*15:10,15:10; C*04:01,03:04; DQA1*05:01,01:01; DQB1*05:01,02:01; DRB1*10:01,03:01 (PubMed=25960936).
CC   HLA typing: A*03:01:01:01; B*15:10,15:CXU; C*03:04:02,04:01:01:01; DPB1*01:01:01; DQA1*01:01:01,05:01:01:01; DQB1*02:01:01,05:01:01; DRA*01:01:01:01; DRB1*03:01:01:01,10:01:01:01; DRB3*02 (IPD-IMGT/HLA=11295).
CC   HLA typing: A*03:01:01; B*15:10:01; C*03:04:02,04:01:01; DPB1*01:01:01; DQA1*01:05:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*03:01:01,10:01:01 (CLS=300359).
CC   HLA typing: A*03:01:01,03:01:01; B*15:10:01,15:10:01; C*03:04:02,04:01:01; DPA1*02:02:02,02:02:02; DPB1*01:01:01,01:01:01; DQA1*01:05:01,05:01:01; DQB1*02:01:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*03:01:01,10:01:01 (DSMZCellDive=ACC-319).
CC   Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6306472; PubMed=6419122; PubMed=6806672).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (PubMed=8344493; PubMed=15901131; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (PubMed=8344493; PubMed=15901131; Cosmic-CLP; DepMap).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: H3K27ac ChIP-seq epigenome analysis.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=99.39%; Native American=0%; East Asian, North=0.6%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Misspelling: BAJI; Cosmic=998718.
CC   Discontinued: ATCC; CRL-7936; true.
CC   Derived from site: In situ; Bone, jaw, maxilla; UBERON=UBERON_0002397.
ST   Source(s): AddexBio; ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; JCRB; PubMed=11416159; PubMed=25877200; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 10,12
ST   D10S1248: 12,13
ST   D12S391: 18,19
ST   D13S317: 13
ST   D16S539: 8,11
ST   D18S51: 17
ST   D19S433: 14,14.2 (CCRID; Genomics_Center_BCF_Technion)
ST   D19S433: 14,15 (DSMZ)
ST   D1S1656: 14
ST   D21S11: 28,31
ST   D22S1045: 15,18
ST   D2S1338: 22 (CCRID; Genomics_Center_BCF_Technion)
ST   D2S1338: 21,22 (DSMZ)
ST   D2S441: 11,12
ST   D3S1358: 15,16
ST   D5S818: 10,13
ST   D7S820: 10
ST   D8S1179: 14,15
ST   DYS391: 10
ST   FGA: 19,27
ST   Penta D: 3.2,9 (CLS; Genomics_Center_BCF_Technion; PubMed=25877200)
ST   Penta D: 3.2,9,10 (DSMZ)
ST   Penta E: 5,13
ST   TH01: 6,7
ST   TPOX: 8,13
ST   vWA: 16,19
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   11Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 47
//
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
//
RX   CelloPub=CLPUB00458;
RA   Treichel R.S.;
RT   "Susceptibility to LAK-mediated cytotoxicity of multidrug-resistant
RT   variants of the human RAJI cell line is not related to expression of
RT   major cellular adhesion molecules.";
RL   Ohio J. Sci. 93:14-18(1993).
//
RX   DOI=10.1007/BF02618370;
RA   Stulberg C.S., Coriell L.L., Kniazeff A.J., Shannon J.E.;
RT   "The animal cell culture collection.";
RL   In Vitro 5:1-16(1970).
//
RX   PubMed=170370; DOI=10.1099/0022-1317-28-2-207;
RA   Adams A., Strander H., Cantell K.;
RT   "Sensitivity of the Epstein-Barr virus transformed human lymphoid cell
RT   lines to interferon.";
RL   J. Gen. Virol. 28:207-217(1975).
//
RX   PubMed=216485;
RA   Higgins N.P., Strauss B.S.;
RT   "Differences in the ability of human lymphoblastoid lines to exclude
RT   bromodeoxyuridine and in their sensitivity to methyl methanesulfonate
RT   and to incorporated [3H]thymidine.";
RL   Cancer Res. 39:312-320(1979).
//
RX   PubMed=1086134;
RA   Kaplan J., Peterson W.D. Jr.;
RT   "Detection of T-cell lymphoma-associated antigens on cord blood
RT   lymphocytes and phytohemagglutinin-stimulated blasts.";
RL   Cancer Res. 36:3471-3475(1976).
//
RX   PubMed=1915267; DOI=10.1002/j.1460-2075.1991.tb07837.x;
RA   Farrell P.J., Allan G.J., Shanahan F., Vousden K.H., Crook T.;
RT   "p53 is frequently mutated in Burkitt's lymphoma cell lines.";
RL   EMBO J. 10:2879-2887(1991).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2470097; DOI=10.1073/pnas.86.9.3257;
RA   Shtivelman E., Henglein B., Groitl P., Lipp M., Bishop J.M.;
RT   "Identification of a human transcription unit affected by the variant
RT   chromosomal translocations 2;8 and 8;22 of Burkitt lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:3257-3260(1989).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=2998993;
RA   Steel C.M., Morten J.E.N., Foster E.;
RT   "The cytogenetics of human B lymphoid malignancy: studies in Burkitt's
RT   lymphoma and Epstein-Barr virus-transformed lymphoblastoid cell
RT   lines.";
RL   IARC Sci. Publ. 60:265-292(1985).
//
RX   PubMed=3026973; DOI=10.1002/ijc.2910390215;
RA   Ehlin-Henriksson B., Manneborg-Sandlund A., Klein G.;
RT   "Expression of B-cell-specific markers in different Burkitt lymphoma
RT   subgroups.";
RL   Int. J. Cancer 39:211-218(1987).
//
RX   PubMed=3034807; DOI=10.1002/ijc.2910390622;
RA   Ohno H., Fukuhara S., Takahashi R., Mihara K.-i., Sugiyama T., Doi S.,
RA   Uchino H., Toyoshima K.;
RT   "c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma
RT   cell line carrying a t(14;18) chromosomal translocation.";
RL   Int. J. Cancer 39:785-788(1987).
//
RX   PubMed=3080238;
RA   Sieverts H., Alabaster O., Goldschmidts W., Magrath I.T.;
RT   "Expression of surface antigens during the cell cycle in different
RT   growth phases of American and African Burkitt's lymphoma cell lines.";
RL   Cancer Res. 46:1182-1188(1986).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=3905596;
RA   Favrot M.-C., Philip I., Philip T., Cabrillat H., Pinatel C.,
RA   Dore J.-F., Lenoir G.M.;
RT   "Immunophenotypic classification of 28 Burkitt cell lines with
RT   monoclonal antibodies and reagent selection for bone-marrow purging.";
RL   IARC Sci. Publ. 60:447-452(1985).
//
RX   PubMed=4122458; DOI=10.1002/ijc.2910100108;
RA   Klein G., Dombos L., Gothoskar B.;
RT   "Sensitivity of Epstein-Barr virus (EBV) producer and non-producer
RT   human lymphoblastoid cell lines to superinfection with EB-virus.";
RL   Int. J. Cancer 10:44-57(1972).
//
RX   PubMed=4169243; DOI=10.1093/jnci/39.5.1027;
RA   Klein G., Clifford P., Klein E., Smith R.T., Minowada J.,
RA   Kourilsky F.M., Burchenal J.H.;
RT   "Membrane immunofluorescence reactions of Burkitt lymphoma cells from
RT   biopsy specimens and tissue cultures.";
RL   J. Natl. Cancer Inst. 39:1027-1044(1967).
//
RX   PubMed=4321017; DOI=10.1002/ijc.2910060315;
RA   Durr F.E., Monroe J.H., Schmitter R., Traul K.A., Hirshaut Y.;
RT   "Studies on the infectivity and cytopathology of Epstein-Barr virus in
RT   human lymphoblastoid cells.";
RL   Int. J. Cancer 6:436-449(1970).
//
RX   PubMed=4321974;
RA   Maurer B.A., Imamura T., Wilbert S.M.;
RT   "Incidence of EB virus-containing cells in primary and secondary
RT   clones of several Burkitt lymphoma cell lines.";
RL   Cancer Res. 30:2870-2875(1970).
//
RX   PubMed=4325933; DOI=10.1093/jnci/46.6.1243;
RA   Pearson G.R., Henle G., Henle W.;
RT   "Production of antigens associated with Epstein-Barr virus in
RT   experimentally infected lymphoblastoid cell lines.";
RL   J. Natl. Cancer Inst. 46:1243-1250(1971).
//
RX   PubMed=4347031; DOI=10.1093/jnci/48.1.87;
RA   Hewetson J.F., Gothoskar B., Klein G.;
RT   "Radioiodine-labeled antibody test for the detection of membrane
RT   antigens associated with Epstein-Barr virus.";
RL   J. Natl. Cancer Inst. 48:87-94(1972).
//
RX   PubMed=4364259; DOI=10.1002/ijc.2910110210;
RA   Klein G., Dombos L.;
RT   "Relationship between the sensitivity of EBV-carrying lymphoblastoid
RT   lines to superinfection and the inducibility of the resident viral
RT   genome.";
RL   Int. J. Cancer 11:327-337(1973).
//
RX   PubMed=4366935;
RA   Minowada J., Nonoyama M., Moore G.E., Rauch A.M., Pagano J.S.;
RT   "The presence of the Epstein-Barr viral genome in human lymphoblastoid
RT   B-cell lines and its absence in a myeloma cell line.";
RL   Cancer Res. 34:1898-1903(1974).
//
RX   PubMed=4550511; DOI=10.1073/pnas.69.1.78;
RA   Hampar B., Derge J.G., Martos L.M., Walker J.L.;
RT   "Synthesis of Epstein-Barr virus after activation of the viral genome
RT   in a 'virus-negative' human lymphoblastoid cell (Raji) made resistant
RT   to 5-bromodeoxyuridine.";
RL   Proc. Natl. Acad. Sci. U.S.A. 69:78-82(1972).
//
RX   PubMed=4736620; DOI=10.1111/j.1469-1809.1973.tb00588.x;
RA   Povey S., Gardiner S.E., Watson B., Mowbray S., Harris H., Arthur E.,
RA   Steel C.M., Blenkinsop C., Evans H.J.;
RT   "Genetic studies on human lymphoblastoid lines: isozyme analysis on
RT   cell lines from forty-one different individuals and on mutants
RT   produced following exposure to a chemical mutagen.";
RL   Ann. Hum. Genet. 36:247-266(1973).
//
RX   PubMed=4894370; DOI=10.1002/1097-0142(196908)24:2<211::AID-CNCR2820240202>3.0.CO;2-3;
RA   Southam C.M., Burchenal J.H., Clarkson B.D. Sr., Tanzi A., Mackey R.,
RA   McComb V.;
RT   "Heterotransplantability of human cell lines derived from leukemia and
RT   lymphomas into immunologically tolerant rats.";
RL   Cancer 24:211-222(1969).
//
RX   PubMed=6018567;
RA   Miles C.P., O'Neill F.;
RT   "Chromosome studies of 8 in vitro lines of Burkitt's lymphoma.";
RL   Cancer Res. 27:392-402(1967).
//
RX   PubMed=6231253; DOI=10.1002/ijc.2910330407;
RA   Ehlin-Henriksson B., Klein G.;
RT   "Distinction between Burkitt lymphoma subgroups by monoclonal
RT   antibodies: relationships between antigen expression and type of
RT   chromosomal translocation.";
RL   Int. J. Cancer 33:459-463(1984).
//
RX   PubMed=6265077;
RA   Pizzo P.A., Chattopadhyay S.K., Magrath I.T., Del Giacco E.,
RA   Sherrick D., Gray T.;
RT   "Examination of Epstein-Barr virus and C-type proviral sequences in
RT   American and African lymphomas and derivative cell lines.";
RL   Cancer Res. 41:3165-3171(1981).
//
RX   PubMed=6286763; DOI=10.4049/jimmunol.129.3.1336;
RA   Benjamin D., Magrath I.T., Maguire R.T., Janus C., Todd H.D.,
RA   Parsons R.G.;
RT   "Immunoglobulin secretion by cell lines derived from African and
RT   American undifferentiated lymphomas of Burkitt's and non-Burkitt's
RT   type.";
RL   J. Immunol. 129:1336-1342(1982).
//
RX   PubMed=6306472; DOI=10.1038/304135a0;
RA   Hamlyn P.H., Rabbitts T.H.;
RT   "Translocation joins c-myc and immunoglobulin gamma 1 genes in a
RT   Burkitt lymphoma revealing a third exon in the c-myc oncogene.";
RL   Nature 304:135-139(1983).
//
RX   PubMed=6419122; DOI=10.1038/306760a0;
RA   Rabbitts T.H., Hamlyn P.H., Baer R.;
RT   "Altered nucleotide sequences of a translocated c-myc gene in Burkitt
RT   lymphoma.";
RL   Nature 306:760-765(1983).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=6547209; DOI=10.1038/309592a0;
RA   Rabbitts T.H., Forster A., Hamlyn P.H., Baer R.;
RT   "Effect of somatic mutation within translocated c-myc genes in
RT   Burkitt's lymphoma.";
RL   Nature 309:592-597(1984).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6592381; DOI=10.1093/jnci/73.4.841;
RA   Favrot M.-C., Philip I., Philip T., Portoukalian J., Dore J.-F.,
RA   Lenoir G.M.;
RT   "Distinct reactivity of Burkitt's lymphoma cell lines with eight
RT   monoclonal antibodies correlated with the ethnic origin.";
RL   J. Natl. Cancer Inst. 73:841-847(1984).
//
RX   PubMed=6600440; DOI=10.1007/BF02617996;
RA   Uittenbogaart C.H., Cantor Y., Fahey J.L.;
RT   "Growth of human malignant lymphoid cell lines in serum-free medium.";
RL   In Vitro 19:67-72(1983).
//
RX   PubMed=6806672; DOI=10.1038/298474a0;
RA   Lenoir G.M., Preud'homme J.-L., Bernheim A., Berger R.;
RT   "Correlation between immunoglobulin light chain expression and variant
RT   translocation in Burkitt's lymphoma.";
RL   Nature 298:474-476(1982).
//
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
//
RX   PubMed=7060222; DOI=10.1016/0009-2797(82)90007-2;
RA   Meltz M.L., Whittam N.J., Thornburg W.H.;
RT   "Reassociation of human lymphoblastoid cell DNA repair replicated
RT   following methyl methanesulfonate treatment.";
RL   Chem. Biol. Interact. 39:77-88(1982).
//
RX   PubMed=7316467; DOI=10.1111/j.1469-1809.1980.tb00953.x;
RA   Povey S., Jeremiah S., Arthur E., Steel M., Klein G.;
RT   "Differences in genetic stability between human cell lines from
RT   patients with and without lymphoreticular malignancy.";
RL   Ann. Hum. Genet. 44:119-133(1980).
//
RX   PubMed=7849311; DOI=10.1182/blood.V85.4.893.bloodjournal854893;
RA   Stranks G., Height S.E., Mitchell P., Jadayel D.M., Yuille M.A.R.,
RA   De Lord C., Clutterbuck R.D., Treleaven J.G., Powles R.L.,
RA   Nacheva E., Oscier D.G., Karpas A., Lenoir G.M., Smith S.D.,
RA   Millar J.L., Catovsky D., Dyer M.J.S.;
RT   "Deletions and rearrangement of CDKN2 in lymphoid malignancy.";
RL   Blood 85:893-901(1995).
//
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
//
RX   PubMed=8344493; DOI=10.1096/fasebj.7.10.8344493;
RA   Bhatia K.G., Goldschmidts W., Gutierrez M.I., Gaidano G., Dalla-Favera R.,
RA   Magrath I.T.;
RT   "Hemi- or homozygosity: a requirement for some but not other p53
RT   mutant proteins to accumulate and exert a pathogenetic effect.";
RL   FASEB J. 7:951-956(1993).
//
RX   PubMed=8515068; DOI=10.4049/jimmunol.150.12.5418;
RA   Jain V.K., Judde J.-G., Max E.E., Magrath I.T.;
RT   "Variable IgH chain enhancer activity in Burkitt's lymphomas suggests
RT   an additional, direct mechanism of c-myc deregulation.";
RL   J. Immunol. 150:5418-5428(1993).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=8847894;
RA   Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K.,
RA   Nakamura H., Amakawa R., Ohno H.;
RT   "Sensitivity to dexamethasone and absence of bcl-2 protein in
RT   Burkitt's lymphoma cell line (Black93) derived from a patient with
RT   acute tumor lysis syndrome: comparative study with other BL and non-BL
RT   lines.";
RL   Leukemia 10:1592-1603(1996).
//
RX   PubMed=9192833;
RA   Cherney B.W., Bhatia K.G., Sgadari C., Gutierrez M.I., Mostowski H.S.,
RA   Pike S.E., Gupta G., Magrath I.T., Tosato G.;
RT   "Role of the p53 tumor suppressor gene in the tumorigenicity of
RT   Burkitt's lymphoma cells.";
RL   Cancer Res. 57:2508-2515(1997).
//
RX   PubMed=9473234; DOI=10.1182/blood.V91.5.1680;
RA   Klangby U., Okan I., Magnusson K.P., Wendland M., Lind P., Wiman K.G.;
RT   "p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a
RT   mRNA and protein expression in Burkitt's lymphoma.";
RL   Blood 91:1680-1687(1998).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
//
RX   PubMed=9737686; DOI=10.1038/sj.leu.2401112;
RA   Zhang W., Ohnishi K., Shigeno K., Fujisawa S., Naito K., Nakamura S.,
RA   Takeshita K., Takeshita A., Ohno R.;
RT   "The induction of apoptosis and cell cycle arrest by arsenic trioxide
RT   in lymphoid neoplasms.";
RL   Leukemia 12:1383-1391(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=9973220;
RA   Gutierrez M.I., Cherney B.W., Hussain A., Mostowski H.S., Tosato G.,
RA   Magrath I.T., Bhatia K.G.;
RT   "Bax is frequently compromised in Burkitt's lymphomas with
RT   irreversible resistance to Fas-induced apoptosis.";
RL   Cancer Res. 59:696-703(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=12145705; DOI=10.1038/sj.leu.2402519;
RA   Langerak A.W., Moreau E., van Gastel-Mol E.J., van der Burg M.,
RA   van Dongen J.J.M.;
RT   "Detection of clonal EBV episomes in lymphoproliferations as a
RT   diagnostic tool.";
RL   Leukemia 16:1572-1573(2002).
//
RX   PubMed=12967475; DOI=10.1111/j.1349-7006.2003.tb01518.x;
RA   Maesako Y., Uchiyama T., Ohno H.;
RT   "Comparison of gene expression profiles of lymphoma cell lines from
RT   transformed follicular lymphoma, Burkitt's lymphoma and de novo
RT   diffuse large B-cell lymphoma.";
RL   Cancer Sci. 94:774-781(2003).
//
RX   PubMed=14086209; DOI=10.1016/S0140-6736(64)92345-1;
RA   Pulvertaft R.J.V.;
RT   "Cytology of Burkitt's tumour (African lymphoma).";
RL   Lancet 283:238-240(1964).
//
RX   PubMed=14982850; DOI=10.1016/S0002-9440(10)63184-7;
RA   Takakuwa T., Luo W.-J., Ham M.F., Sakane-Ishikawa E., Wada N.,
RA   Aozasa K.;
RT   "Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt
RT   lymphoma cell line (Raji) induces loss of BACH2 expression.";
RL   Am. J. Pathol. 164:967-974(2004).
//
RX   PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x;
RA   Kamimura K., Hojo H., Abe M.;
RT   "Characterization of expression of protein kinase C isozymes in human
RT   B-cell lymphoma: relationship between its expression and prognosis.";
RL   Pathol. Int. 54:224-230(2004).
//
RX   PubMed=15457187; DOI=10.1038/sj.leu.2403534;
RA   Karpova M.B., Schoumans J., Ernberg I., Henter J.-I., Nordenskjold M.,
RA   Fadeel B.;
RT   "Raji revisited: cytogenetics of the original Burkitt's lymphoma cell
RT   line.";
RL   Leukemia 19:159-161(2005).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=18357372; DOI=10.3892/or.19.4.889;
RA   Pop I., Pop L., Vitetta E.S., Ghetie M.-A.;
RT   "Generation of multidrug resistant lymphoma cell lines stably
RT   expressing P-glycoprotein.";
RL   Oncol. Rep. 19:889-895(2008).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22885699; DOI=10.1038/nature11378;
RA   Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W.-M., Zhang M.-L.,
RA   Wright G., Shaffer A.L. III, Hodson D.J., Buras E., Liu X.-L., Powell J.I.,
RA   Yang Y.-D., Xu W.-H., Zhao H., Kohlhammer H., Rosenwald A., Kluin P.,
RA   Muller-Hermelink H.-K., Ott G., Gascoyne R.D., Connors J.M.,
RA   Rimsza L.M., Campo E., Jaffe E.S., Delabie J., Smeland E.B.,
RA   Ogwang M.D., Reynolds S.J., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pittaluga S., Wilson W.,
RA   Waldmann T.A., Rowe M., Mbulaiteye S.M., Rickinson A.B., Staudt L.M.;
RT   "Burkitt lymphoma pathogenesis and therapeutic targets from structural
RT   and functional genomics.";
RL   Nature 490:116-120(2012).
//
RX   PubMed=24590883; DOI=10.1002/gcc.22161;
RA   Murga Penas E.-M., Schilling G., Behrmann P., Klokow M.,
RA   Vettorazzi E., Bokemeyer C., Dierlamm J.;
RT   "Comprehensive cytogenetic and molecular cytogenetic analysis of 44
RT   Burkitt lymphoma cell lines: secondary chromosomal changes
RT   characterization, karyotypic evolution, and comparison with primary
RT   samples.";
RL   Genes Chromosomes Cancer 53:497-515(2014).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27566572; DOI=10.18632/oncotarget.11524;
RA   Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V.,
RA   MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C.,
RA   Zaborski M., Drexler H.G.;
RT   "Subclones in B-lymphoma cell lines: isogenic models for the study of
RT   gene regulation.";
RL   Oncotarget 7:63456-63465(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29892436; DOI=10.1098/rsos.172472;
RA   Shioda S., Kasai F., Watanabe K., Kawakami K., Ohtani A., Iemura M.,
RA   Ozawa M., Arakawa A., Hirayama N., Kawaguchi E., Tano T., Miyata S.,
RA   Satoh M., Shimizu N., Kohara A.;
RT   "Screening for 15 pathogenic viruses in human cell lines registered at
RT   the JCRB Cell Bank: characterization of in vitro human cells by viral
RT   infection.";
RL   R. Soc. Open Sci. 5:172472-172472(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//